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Edited by Lukas HuberAbstract The pituitary tumor transforming Gene (PTTG) is an
oncogene that is highly expressed in most tumors analyzed to
date. Here, we report the eﬀects of insulin and the insulin like
growth factor-1 (IGF-1) on the expression of PTTG. Using
MCF-7 cells, a human breast cancer cell line, we observed that
both insulin and IGF-1 upregulate the expression of PTTG
mRNA by approximately 2.5-fold. Induction of PTTG mRNA
expression by insulin or IGF-1 was completely blocked by the spe-
ciﬁc phosphatidylinositol (PI) 3 kinase inhibitor LY294002, but
partially blocked by the MAP kinase inhibitor PD98059. Pre-
treatment ofMCF-7 cells with actinomycin D completely blocked
the stimulatory eﬀect of insulin. Transfection ofMCF-7 cells with
a PTTG promoter-luciferase reporter construct revealed the
dose-dependent stimulation of PTTG promoter activity by insu-
lin, suggesting that the increase in PTTG expression by insulin
is a result of activation of transcription of the PTTG gene. Taken
together, our results suggest that insulin and IGF-1 regulate the
expression of PTTG in MCF-7 cells primarily through the acti-
vation of PI3K/AKT cascade.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Pituitary tumor transforming gene (PTTG), also referred as
securin is a newly isolated oncogene that was initially cloned
from a rat pituitary tumor [1]. Human PTTG cDNA encodes
a protein of 203 amino acids that is predominately located in
the cytoplasm with partial nuclear localization [2]. In normal
tissues, with the exception of the testis and thymus, PTTG
expression is low or absent [3]. However, in rapidly proliferat-
ing cells and various tumors from pituitary, colon, thyroid, tes-
tis, ovary and breast, PTTG expression is highly activated, and
the protein is overexpressed [4–8]. In addition to PTTG being
overexpressed in breast tumors, relative to normal breast epi-
thelium [9] PTTG mRNA expression has been reported to
serves as a marker for lymph node invasion and tumor recur-
rence [8]. As an oncogene, PTTG is a multifunctional protein
that stimulates the expression and secretion of mitogenic and*Corresponding author. Fax: +1 502 852 2356.
E-mail address: sskaka01@gwise.louisville.edu (S.S. Kakar).
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PTTG inhibits chromatid separation by inhibiting separase
[11], and processes transcriptional activation capability [12].
PTTG directly binds to the c-myc promoter sequence and
upregulates its expression. Recently, we demonstrated that
PTTG modulates the expression and function of p53 [13].
Although various advances have contributed to new knowl-
edge pertaining to PTTG, the information regarding which
mitogens regulate the expression and function of PTTG is lim-
ited. Recently, Tfelt-Hansen et al. [14] reported regulation of
PTTG expression in human astrocytes cell, by two promalig-
nant mitogens, the epithelial growth factor (EGF) and TGFa.
Analysis of PTTG gene sequence revealed the existence of a
potential insulin response sequence in the 5 0 ﬂanking region
[15], suggesting that insulin may regulate PTTG expression.
In addition, Clem et al. [16] demonstrated the regulation of
PTTG promoter activity by Sp1 nuclear factor, a well known
downstream target of insulin in tumor cells [17]. Collectively,
these observations suggested the existence of a regulatory rela-
tionship between insulin and PTTG.
Insulin is a potent anabolic growth factor that regulates
numerous cellular functions. As a mitogen, insulin stimulates
carbohydrate metabolism, DNA synthesis, and cell prolifer-
ation by binding to and activating a tyrosine kinase
receptor. Multiple signaling pathways downstream of the
receptor involving PI 3-kinase AKT (PI3K/AKT) and Ras-
MAPK pathways are activated by insulin [18,19]. In cancer
cells, these insulin regulated pathways may contribute to the
growth and proliferation of tumors by activating oncogenic
molecular targets such as PTTG. In addition, the insulin-like
growth factor-1 (IGF-1) activates the similar signaling path-
ways that are downstream of the tyrosine kinase insulin
receptor. Mitogenically, the bioavailability of insulin and
IGF-1 is known to contribute to tumor development [20].
For example, increased levels of the insulin receptor,
IGF-1 receptor, and hybrid insulin/IGF-1 receptors have
been identiﬁed in breast carcinomas [21–23]. IGF-1 has been
shown to enhance the survival of chemotherapy-treated
breast cancer cells [24]. In the present study, we used
MCF-7 human breast cancer cells, as our model. The ra-
tional for using MCF-7 cells, was dependent on the cell lines
ability to endogenously express PTTG and both the insulin
and IGF receptors [3,25–27]. Our results show that PTTG
mRNA and protein expression is signiﬁcantly increased by
insulin and IGF-1. This stimulation may contribute to
tumor growth and progression.ation of European Biochemical Societies.
Fig. 1. Insulin stimulates PTTG mRNA expression in human breast
cancerMCF-7 cells in a time-dependent manner. Serum starvedMCF-7
cells were treated with 10 nM of insulin for 12, 24, or 48 h. Ten lg of
total RNAwas separated on agarose/formaldehyde gel and subjected to
Northern blot analysis. Hybridization was performed with 32P labeled
PTTG full length cDNA. Expression of PTTG was normalized with
GAPDH. Lower panel is graphical representation of Northern blot.
The data shown are representative of two independent experiments.
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2.1. Materials
Human recombinant insulin, IGF-1, Trizol, and actinomycin D
were obtained from Invitrogen Inc. (Carlsbad, CA). Polyclonal anti-
body against phospho AKT and monoclonal antibody against total
AKT were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Polyclonal antibody against phospho-ERK1/2 and monoclonal
antibody against total ERK were obtained from Cell Signaling Tech-
nology, Inc. (Beverly, MA). Polyclonal anti-serum against PTTG
was previously raised in our laboratory [28]. Goat anti-rabbit IgG
horseradish peroxidase (HRP) linked antibody, goat anti-mouse
HRP linked antibody, enhanced chemiluminescence (ECL) supplies,
[a-32P] dCTP, nylon membrane Hybond-N, and nitrocellulose mem-
brane Hybond-ECL were purchased from Amersham Biosciences.
Materials for SDS–PAGE were purchased from Bio-Rad Laboratories
(Richmond, CA). The PI3K/AKT inhibitor LY294002 was purchased
from Cayman Chemical (Ann Arbor, MI) and the MAPK inhibitor
PD98059 was from Sigma Chemical Co. (St. Louis, MO).
2.2. Cell culture
MCF-7 cells were obtained from American Type Culture Collection
(ATCC). Cells were maintained in Dulbeccos Modiﬁed Eagle Medium
(DMEM) with 10% fetal bovine serum at 5% CO2 and 37 C. Conﬂu-
ent cells were split and seeded into 6-well plates and incubated for 18–
24 h. Media were removed and replaced with serum-free media and
cells were treated with various reagents as described in the ﬁgure leg-
ends.
2.3. RNA extraction and Northern blot
Total RNA was isolated using Trizol (Invitrogen Inc., Carlsbad,
CA), and the quantity of RNA was determined using a spectropho-
tometer. Ten micro gram of total RNA was separated on a 1.5% aga-
rose/formaldehyde gel, transferred to a nylon membrane Hybond-N
(Amersham Biosciences, UK), and crosslinked as described previously
[3]. The membrane was prehybridized for 20 min at 65 C in Expres-
sHyb Buﬀer (Clonetech Laboratories Inc., Palo Alto, CA). PTTG
cDNA, GAPDH cDNA, or 18S cDNA was labeled with [a-32P] dCTP
using a random hexamer primer labeling kit (Promega Co., Madison,
WI). Hybridization was performed with the labeled probe (approxi-
mately 5 · 106 cpm/ml) for 1 h in fresh hybridization buﬀer at 65 C.
The membrane was washed twice in 2· SSC/0.1% SDS for 15 min each,
and washed once for 15 min at 55 C in 0.2· SSC/0.1% SDS. The blot
was initially hybridized with 32P-labeled PTTG cDNA. Thereafter, the
membrane was stripped and then rehybridized with 32P-labeled
GAPDH or 18S cDNA. PTTG, GAPDH, or 18S bands were quanti-
ﬁed using the Molecular Analyst Program (Bio-Rad Laboratories,
Hercules, CA). Values for PTTG were normalized with either GAPDH
or 18S.
2.4. Transient transfections and measurements of PTTG promoter
activity
Human PGL3-PTTG promoter-luciferase construct (1.3 kb) was uti-
lized for transient transfections [14]. Approximately 3.0 · 105 cells/well
were plated in 6-well plates and maintained in 10% fetal bovine serum/
DMEM for 18–24 h. Fugene-6 (Roche Diagnostics, Nutley, NJ) was
utilized as a transfection reagent and 1 lg/well of PTTG plasmid and
100 ng/well of b-gal control reporter plasmid were co-transfected
according to suppliers instructions (Promega Co.). All transient trans-
fection experiments were conducted in 10% charcoal-treated FBS/
DMEM. After 24 h of transfection, cells were serum-starved for 24 h
and then treated with the indicated concentrations of insulin for
24 h. Cells were harvested in luciferase cell culture lysis buﬀer (Prome-
ga Co.). Lysate was centrifuged at 10000 rpm for 5 min. The superna-
tant was used to determine luciferase and b-gal activities, and
luciferase activity was normalized with b-gal activity.
2.5. Immunoblot analysis
After each indicated treatment, the MCF-7 cells were washed with
PBS buﬀer and harvested with a lysis buﬀer (50 mM Tris–Cl,
100 mM NaCl, and 0.1% Triton-100·). A Bradford protein assay
(Bio-Rad Laboratories Inc., Hercules, CA) was used to determine pro-
tein concentration. Equal amounts of protein (40 lg) from each sam-ple, were resolved on a 15% SDS–polyacrylamide gel and transferred
to a Hybond-ECLmembrane (Amersham Biosciences). Blots were then
blocked in Tris buﬀered saline solution with 0.1% of Tween-20 (TBST)
and 5% of nonfat milk for 1 h at room temperature followed by incu-
bation with anti-PTTG serum overnight at 4 C. The blots were
washed three times, for 10 min each in TBST. The blots were then
incubated with horseradish peroxidase-conjugated anti-rabbit second-
ary IgG for 45 min. The immuno-reactive bands were detected using
the ECL system (Amersham Biosciences). The blots were stripped
and re-probed with b-actin antibody to determine equal loading of
protein for each sample.
The serine phosphorylation of AKT and the tyrosine phosphoryla-
tion of the ERK1/2 proteins were detected using SDS–PAGE. Prior
to transferring to a nitrocellulose membrane, 40 lg of total cell lysate
was resolved by 10% SDS–PAGE. The immunoblot was incubated
overnight at 4 C with antibody against phosphor-(Ser-473)-AKT, to-
tal AKT, tyrosine-phosphorylated ERK 1/2, or total ERK 1/2. The
blots were washed three times with TBST and immuno-reactive bands
were detected using the HRP-conjugated antibody and ECL kit as de-
scribed above.3. Results
3.1. Insulin stimulates PTTG expression in a time-dependent
manner
We ﬁrst studied the time-dependent eﬀect of insulin on
PTTG mRNA expression. Serum starved MCF-7 cells were
treated with 10 nM insulin for various time points. Levels of
PTTG mRNA were analyzed using Northern blot anlaysis.
As shown in Fig. 1, treatment of cells with 10 nM of insulin
for 24 h resulted in an approximately 2.5-fold increase in
Fig. 2. Insulin stimulates PTTG mRNA and protein expression in
MCF-7 cells in a dose-dependent manner. A: Serum starved MCF-7
cells were treated with various concentrations of insulin for 24 h. Ten
lg of total RNA was separated agarose/formaldehyde gel and
subjected to Northern blot analysis. Hybridization was performed
using 32P-labeled PTTG cDNA. Expression of PTTG was normalized
with 18S. Lower panel is graphical representation of Northern blot . B:
MCF-7 cells were treated 1 nM or 10 nM insulin for 48 h and then
washed with PBS and lysed in lysis buﬀer. Forty lg of protein from
each sample was used for Western blot analysis. PTTG antiserum was
used for PTTG protein analysis. b-actin antibody was used as a control
to determine equal protein loading for each sample. The data shown
are representative of two independent experiments.
Fig. 3. IGF-1 stimulates PTTG mRNA expression in human MCF-7
cells. A: Serum starved cells were treated with IGF-1 to a ﬁnal
concentration of 20 ng/ml for 24 h. Ten lg of total RNA was separated
on agarose/formaldehyde gel and subjected to Northern blot analysis.
Hybridizationwas performedwith 32P-labeled PTTG full length cDNA.
Expression of PTTGwas normalized with 18S. Lower panel is graphical
representation of Northern blot. B: MCF-7 cells after treatment with
IGF-1 (20 ng/ml), washed with PBS and lysed in lysis buﬀer. Forty lg of
protein from each sample was used for Western blot analysis. PTTG
antiserum was used for PTTG protein analysis. b-actin antibody was
used as a control to determine equal protein loading for each sample. The
data shown are representative of two independent experiments.
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Maximum inductive eﬀect of 3.5-fold was observed after 48 h
of treatment. There was no signiﬁcant rise by insulin on PTTG
expression before 12 h of treatment.
3.2. Insulin induces PTTG mRNA and protein expression in a
concentration-dependent manner
We next examined the dose-dependent eﬀects of insulin on
PTTG expression. We treated serum-starved MCF-7 cells with
1, 10 or 100 nM insulin, and determined the PTTG mRNA lev-
els after 24 h of treatment. Insulin stimulated PTTG mRNA
expression in a dose-dependent fashion (Fig. 2A). A 2.5-fold
increase was observed with 10 nM insulin. These results are
consistent with those shown in Fig. 1. Western blot analysis
of cells treated with insulin showed a similar increase in PTTG
protein levels (Fig. 2B). Considering that insulin and IGF-1
may bind to the same receptor and activate the same signaling
pathways [29], insulins ability to stimulate the expression of
PTTG led us to examine the eﬀect of IGF-1 on PTTG expres-
sion. As shown in Fig. 3A, similar to the insulin eﬀect, treat-
ment of MCF-7 cells with IGF-1 (20 ng/ml) resulted in a
2.5-fold increase in PTTG mRNA expression. Protein levels
were also increased after 24 h of treatment. The regulation of
PTTG expression by insulin and IGF-1 appears to contribute
to increased mRNA and protein levels of PTTG. Our results
do not suggest that any post-translational modiﬁcations
occurred to PTTG protein.3.3. Insulin induces the activation of PI3K/AKT and Ras-MAPK
pathways in MCF-7 cells
Both insulin and IGF-1 showed activation of PTTG expres-
sion and both insulin and IGF-1 mediate their downstream
eﬀects via two major signaling pathways; PI3K/AKT and
Ras-MAPK [30]. To determine which of these two pathways
are activated by insulin and IGF-1, we used speciﬁc pharmaco-
logical inhibitors for each of pathway. Initially, we treated
MCF-7 cells with 10 nM insulin and monitored the short-term
phosphorylation of AKT and ERK1/2. Within approximately
within 5 min of treatment, insulin stimulated AKT and ERK1/
2 phosphorylation which reached maximum levels within
30 min (Fig. 4A and B). Pretreatment of cells with the PI3K/
AKT-speciﬁc inhibitor LY294002 (50 lM) completely blocked
the insulin-induced phosphorylation of AKT (Fig. 4C). Treat-
ment of cells with insulin or IGF-1 induced PTTG mRNA
expression, however, pretreatment of cells with LY294002
completely blocked the insulin- and IGF-1-induced PTTG
mRNA expression (Fig. 5A and B). Pretreatment of cells with
Ras-MAPK-speciﬁc inhibitor PD98059 (10 lM) partially
blocked the stimulatory eﬀect of insulin and IGF-1 (Fig. 5A
and B), suggesting that both insulin and IGF-1 regulate the
expression of PTTG mRNA through the activation of both
PI3K/AKT and MAPK signaling pathways, but predomi-
nately through the activation of PI3K/AKT cascade.
3.4. Insulin stimulates new synthesis of PTTG mRNA
Having shown that insulin upregulates the expression of
PTTG mRNA, the increase could be due to increased stability
Fig. 5. Eﬀects of PI3K/AKT inhibitor LY294002 (LY), and MAPK inhibitor
IGF-1. Serum starved cells were pretreated with 50 lMLY294002 or 10 lMP
ml IGF-1 for 24 h (B). Ten lg of total RNA from each sample was separated
using 32P-labled PTTG full length cDNA. Expression of PTTG was normal
blots. Data shown represent mean ± SEM of three independent experiments
Fig. 4. Insulin activates PI3K and MAPK pathways in MCF-7 cells.
Serum starved cells were treated with 10 nM of insulin for the
indicated times prior to harvesting. Forty lg of total cell lysate was
separated on an SDS/PAGE gel and transferred to a nitrocellulose
membrane. A: Blot was probed with polyclonal SER 473 phospho-
AKT (p-AKT) antibody. B: Blot was probed with polyclonal
phospho-ERK1/2 (p-ERK) antibody. The blots were stripped and
re-probed and normalized with monoclonal total-AKT antibody (A)
or polyclonal total ERK antibody respectively (B). C: Cells
were pretreated with 50 lM LY294002 for 30 min prior to insulin
treatment. The data shown are representative of two independent
experiments.
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Therefore, to diﬀerentiate between these two processes, we
conducted an experiment using actinomycin D, an inhibitor
of transcription. Pretreatment of MCF-7 cells with actinomy-
cin D (10 lg/ml for 30 min), in the absence of insulin, reduced
the steady state level of PTTG mRNA (Fig. 6A). Insulin alone
increased PTTG mRNA expression, whereas actinomycin
completely blocked the insulin-induced PTTG mRNA expres-
sion. Further, to conﬁrm that insulin stimulated PTTG mRNA
synthesis, a 1.3 kb PTTG promoter-luciferase construct was
transiently transfected into MCF-7 cells prior to treatment
with various concentrations of insulin for 24 h. As shown in
Fig. 6B, insulin stimulated the PTTG promoter activity in a
dose-dependent manner. A maximum eﬀect of 1.8-fold, sim-
ilar to rise in the endogenous PTTG levels illustrated in Fig. 1
was observed when MCF-7 cells were treated with 10 or
100 nM of insulin. A slight decline from the maximum 1.8-fold
induction was seen with the 1000 nM insulin treatment which
could be to due to a downregulation of the insulin receptor.
Collectively, these results indicate that insulin contributes to
the synthesis of PTTG mRNA.4. Discussion
Our results show that physiological concentrations of insulin
and IGF1-1 increase the expression of PTTG in MCF-7 cells.
Insulin activates the PTTG promoter and induces the expres-
sion of endogenous PTTG in a time- and dose-dependent man-
ner. These results, in conjunction with actinomycin D
experiments, indicate that the insulin-induced PTTG expres-
sion is mainly dependent on new synthesis of PTTG mRNA
and may not be due to change in stability of PTTG mRNA.
Finally, our results demonstrate that the insulin- and IGF-1 in-
duced expression of PTTG is primarily through activation of
the PI3K/AKT signaling pathway in MCF-7 cells.PD98059 (PD) on PTTG mRNA expression stimulated by insulin and
D98059 for 30 min and then treated with 10 nM of insulin (A) or 20 ng/
on agarose/formaldehyde gel and subjected to Northern blot analysis
ized with 18S. Lower panels are graphical representation of Northern
(A) and two independent experiments (B).
Fig. 6. Eﬀect of insulin on PTTG mRNA synthesis and promoter activity in MCF-7. A: Serum starved MCF-7 cells were pretreated with
actinomycin (10 lg/ml) for 30 min and then treated with 10 nM insulin for 24 h. Expression of PTTGmRNA was analyzed as described in Fig. 5. The
insulin-stimulated PTTG mRNA transcription was inhibited by actinomycin D. B: MCF-7 cells were co-transfected with PGL3-PTTG promoter
luciferase construct and b-gal plasmid DNA. After 24 h of transfection, cells were starved for 24 h and then treated with various concentration of
insulin for 24 h. Cell lysates were assayed for luciﬁerase and b-gal activities. Luciferase activity was normalized with b-gal which was used as an
internal control. The data shown represent mean ± SEM of three independent experiments.
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functional oncogene, PTTG is a novel ﬁnding. This is an alter-
native non-classical function of insulin. Classical studies
associate insulins function with the regulation of carbohydrate
metabolism [30]. However, this research reveals that insulin
has the ability to increase the transcription of PTTG, a known
oncogene, in a continuous long-term manner with a maximum
eﬀect observed at 48 h (Fig. 1). Increase in expression of PTTG
in mouse ﬁbroblast (NIH 3T3) and in human embryonic kid-
ney (HEK293) cells results in an increase in cell proliferation,
an induction in cellular transformation and promotes tumor
formation in nude mice [3,31]. Induction of PTTG by insulin
and IGF-1 suggests a mechanism by which insulin and IGF-
1 may contribute to the development and/or progression of tu-
mors. In addition, our ﬁndings provide novel insight to growth
factors and signaling mechanisms that regulate the expression
of PTTG. We showed for the ﬁrst time that PI3K/AKT signal-
ing is involved in inducing the expression of PTTG. As a re-
sult, insulin and IGF-1 related signaling cascades (i.e., PI3K/
AKT), may serve as a potential molecular target for cancer
treatment.
Hyperinsulinemia, is characteristic of obese and type 2 dia-
betic patients. Hyperinsulinemia and insulin resistance have
been classiﬁed as a risk factor for breast cancer [32,33] and
hyperinsulinemia also serves as a marker for increased cancer
risk in obese post-menopausal women [34]. In a study by Josef-
son [35], a correlation between hyperinsulinemia and breast
cancer-related deaths was reported. Milazzo et al. [26] and
Van Der Burg et al. [36] reported that insulin regulates the
growth and metabolism of breast cancer cells both in vitro
and in vivo. In our previous studies, we reported a high level
of expression of PTTG mRNA and protein in various breast
tumors [3,7]. Increased levels of insulin receptor, IGF-1 recep-
tor, and hybrid insulin/IGF-1 receptors have been identiﬁed in
breast carcinomas [21–23]. IGF-1 has been shown to enhance
the survival of chemotherapy-treated breast cancer cells [24].
Eﬀects of insulin on tumor development and progression have
been suggested to predispose obese and/or hyperinsulinemic
patients to cancer. Our results support this hypothesis. How-
ever, a detailed target and or signaling pathway to support
the preceding notion remains undeﬁned. Although our work
implies that PTTG may be a downstream target of insulin
and IGF-1, at present, it remains unclear whether induction
of PTTG by insulin and IGF-1 leads to tumorigenesis.In conclusion, we report that insulin and IGF-1 stimulate
PTTG expression in breast cancer cells by stimulating the
PI3K/AKT signaling pathway. Our studies provide novel evi-
dence that insulin and IGF-1 play a role in regulating the
expression of a known oncogene, PTTG. During the time this
paper was being reviewed, a paper related to similar work was
published in Biochem. Biophys. Res. Commun. [37].
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